Cell Therapeutics, Inc.(CTIC)

Description: Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.

---

Keywords: Cancer Organic Compounds Chemical Compounds Breast Cancer Cancer Treatment Lymphoma Ovarian Cancer Acute Myeloid Leukemia Treatment Of Breast Cancer Ethers Head And Neck Cancer Antibody Drug Conjugate Treatment Of Acute Myeloid Leukemia Brain Cancer Triple Negative Breast Cancer Myelofibrosis Treatment Of Ovarian Cancer Pyrrolidines Hodgkin Lymphoma Camidanlumab Tesirine Janus Kinase Treatment Of Head And Neck Cancer Pacritinib Pixantrone Treatment Of Triple Negative Breast Cancer

---

Home Page: www.ctibiopharma.com

CTIC Technical Analysis

3101 Western Avenue
Seattle, WA 98121
United States
Phone: 206 282 7100

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)